Molecular Diagnostics Market: Market Size & Forecast 2026

Molecular diagnostics encompasses laboratory tests that analyze DNA, RNA, and proteins to identify pathogens, genetic mutations, and biomarkers. The field has grown substantially since the early 2000s, driven by reduced sequencing costs, automation improvements, and growing clinical adoption across oncology, infectious disease, and genetic disorders.

• •Market size estimated at approximately $20.55 billion in 2025, with projections to reach roughly $30.74 billion by 2030
• •Includes technologies such as PCR, real-time PCR, in situ hybridization, DNA sequencing, and microarrays
• •Serves hospitals, diagnostic laboratories, academic research institutions, and point-of-care settings

The demand for personalized and precision medicine is a primary catalyst, as molecular tests increasingly guide targeted therapy selection in oncology and chronic disease management. Infectious disease testing, highlighted by the COVID-19 pandemic, has accelerated both investment and regulatory pathways for nucleic acid amplification tests.

• •Rising global incidence of cancer and other chronic diseases driving need for companion diagnostics and liquid biopsies
• •Aging populations in developed and emerging economies increasing demand for early and accurate disease detection
• •Government and private sector investment in genomic sequencing infrastructure supporting long-term market expansion

By technology, PCR-based methods remain the largest segment, while next-generation sequencing is the fastest-growing category due to falling costs and widening clinical utility. By application, oncology currently leads, followed by infectious disease and genetic testing.

• •North America holds the largest market share, supported by advanced healthcare infrastructure and favorable reimbursement policies
• •Europe represents the second-largest region, with strong adoption in Germany, the UK, and France
• •Asia-Pacific is the fastest-growing regional market, led by China, India, and Japan, driven by healthcare modernization and rising disease burden

What are the recent trends and outlook?

The convergence of artificial intelligence with genomic data interpretation, the miniaturization of testing platforms, and the expansion of direct-to-consumer genetic testing are reshaping the competitive and regulatory environment. Over the 2025-2030 forecast period, the market is expected to sustain mid-to-high single-digit growth as molecular diagnostics become further embedded in standard clinical workflows.

• •Point-of-care molecular testing is gaining momentum, enabling faster clinical decisions outside traditional laboratory settings
• •Multiplex assays that simultaneously detect multiple targets are reducing turnaround time and improving cost efficiency
• •Increased focus on liquid biopsy and cell-free DNA technologies is opening new opportunities in cancer screening and monitoring